This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages) |
Marco Marra | |
---|---|
Born | Berwyn, Alberta, Canada | June 30, 1966
Education | Simon Fraser University (PhD – Genetics, BSc – Molecular & Cell Biology) |
Known for | Genomics, Bioinformatics, Cancer Biology, Genetics, Epigenomics, Personalized OncoGenomics (POG) |
Title | Director, Michael Smith Genome Sciences Centre, BC Cancer Distinguished Scientist, BC Cancer Research Institute, BC Cancer Professor, Department of Medical Genetics, University of British ColumbiaContents |
Website | www.bcgsc.ca |
Marco A. Marra is a Distinguished Scientist and Director of Canada's Michael Smith Genome Sciences Centre at the BC Cancer Research Centre and Professor of Medical Genetics at the University of British Columbia (UBC). He also serves as UBC Canada Research Chair in Genome Science for the Canadian Institutes of Health Research and is an inductee in the Canadian Medical Hall of Fame. Marra has been instrumental in bringing genome science to Canada by demonstrating the pivotal role that genomics can play in human health and disease research.
Canadian born and educated, Dr. Marco Marra received a B.Sc. in Molecular & Cell Biology and a PhD in Genetics from Simon Fraser University. The title of his PhD thesis: “Genome analysis in Caenorhabditis elegans: Genetic and molecular identification of genes tightly linked to unc-22(IV)”. [1]
Marra trained as a post-doctoral fellow at the Washington University School of Medicine in St Louis, Missouri. He went on to become Group Leader of both the EST (Express Sequence Tag) Sequencing Team and Genome Fingerprinting and Mapping Teams at Washington University in St. Louis’s Genome Sequence Center (renamed the McDonnell Genome Institute), one of the top two sequencing centers in the world at that time. [2]
In 1998, Nobel Laureate Dr. Michael Smith and Dr. Victor Ling set out to establish the Genome Sequence Centre in Vancouver. At their request, Marra returned to British Columbia to head the Mapping and Sequencing teams.
During his first two years with British Columbia’s Genome Sequence Center (renamed Canada's Michael Smith Genome Sciences Centre), Marra served as head of the Mapping and Sequencing teams, Associate Director and Scientific Co-Director. He also held the position of Senior Scientist at BC Cancer Research and Adjunct Professor for the Department of Medical Genetics. Marra subsequently became Professor and Head of the Department of Medical Genetics in the Faculty of Medicine at UBC.
From 2011 to 2018, Marra founded and co-directed the Genome Science and Technology Graduate Program at UBC. He also lent his expertise to the Department of Molecular Biology and Biochemistry at Simon Fraser University, serving as Adjunct Professor from 2001 to 2015. Marra currently holds the position of BC Node Leader for the Terry Fox Research Institute.
Marra took over as Director of Canada's Michael Smith Genome Sciences Centre (GSC) when Dr. Smith died of cancer in 2000. As of 2021, the GSC has more than 280 scientists, trainees and staff and a grant funding level averaging more than 25 million dollars each year. Marra has mentored many scientists and graduate students who are now providing the expertise and insight needed to fulfill the promise of genomics through technological innovation, enhanced informatics and creative clinical applications.
Along with GSC co-director, Dr. Steven J.M. Jones, Marra was instrumental in creating the first map the human genome, an international initiative that allowed the data to remain in the public domain. One of the largest collaborative scientific projects in history, the Human Genome Project begun in 1990 and completed in 2003. The massive and unprecedented scale of genomic data provided by the Human Genome Project has since revolutionized our understanding of disease biology ranging from cancer to cognitive impairment and continues to unfold new possibilities for integrating laboratory research and clinical practice to improve cancer control.
The paper published in the 15 February 2001 issue of Nature, titled "A physical map of the human genome", [3] describes the construction and use of the human genome map to fuel human genome sequencing. Marra made fundamental contributions to that effort by devising and then implementing clonal fingerprinting [4] techniques that led to the construction and use of the map, which served as the centralized coordinating resource for the sequencing effort.
Led by Marra, the GSC was first in the world to sequence the SARS virus [5] in 2003. Using this information they were the first to identify SARS as a coronavirus. This discovery, along with knowledge of the SARS genome, had significant implications for many infectious diseases and vaccine development. Sequencing techniques used for SARs were also applied to many fields of research and discovery, including cancer.
In 2020, the GSC joined the Canadian COVID Genomics Network (CanCOGeN), a Genome Canada initiative to generate accessible and usable genomics data to inform COVID-19 public health decisions. The GSC was one of the first three facilities involved in sequencing 10,000 Canadians that tested positive for the virus (HostSeq) for this Government of Canada funded project. Research co-led by Marra also identified an alternative procedure for extracting nucleic acids for COVID-19 testing. [6]
As part of a GSC initiative, Marra played a pivotal role in the first proof-of-concept [7] for the effective use of whole genome analyses in personalized cancer medicine, leading to the development of BC Cancer’s Personalized OncoGenomics (POG) program. POG, co-led by Dr. Janessa Laskin, represents one of the first applications of whole genome sequencing in a clinical setting, using information derived from thousands of individual cancer genomes and transcriptomes to identify promising therapeutic targets in individual patients.
In 2019, Marra and the POG team became a key part of the Marathon of Hope Cancer Centres Network. Led by the Terry Fox Research Institute and the Terry Fox Foundation, with support from dozens of research and funding partners across Canada, this represents the country’s largest ever clinical data-sharing initiative. The Marathon of Hope aims to accelerate the adoption of precision medicine for cancer patients throughout Canada.
Marra continues to extend the reach of genomics toward managing and eradicating disease. His research has uncovered new cancer mutations, candidate biomarkers and therapeutic targets, and has been instrumental in demonstrating the functional interplay between the cancer genome and epigenome.
Since 2014, Dr. Marra has been listed in the yearly Highly Cited Researchers and World’s Most Influential Scientific Minds by Thomson Reuters and Clarivate Analytics. This list recognizes world-class researchers selected for their exceptional research performance, demonstrated by production of multiple highly cited papers that rank in the top 1% by citations for field and year in Web of Science.
Marra's contributions to genome science led to an honorary Doctor of Science degree from Simon Fraser University in 2004, and an honorary Doctor of Laws degree from the University of Calgary in 2005. He is also a recipient of the Order of British Columbia [8] and became a member of the Canadian Medical Hall of Fame in 2020. [9]
In genetics, shotgun sequencing is a method used for sequencing random DNA strands. It is named by analogy with the rapidly expanding, quasi-random shot grouping of a shotgun.
The human genome is a complete set of nucleic acid sequences for humans, encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria. These are usually treated separately as the nuclear genome and the mitochondrial genome. Human genomes include both protein-coding DNA sequences and various types of DNA that does not encode proteins. The latter is a diverse category that includes DNA coding for non-translated RNA, such as that for ribosomal RNA, transfer RNA, ribozymes, small nuclear RNAs, and several types of regulatory RNAs. It also includes promoters and their associated gene-regulatory elements, DNA playing structural and replicatory roles, such as scaffolding regions, telomeres, centromeres, and origins of replication, plus large numbers of transposable elements, inserted viral DNA, non-functional pseudogenes and simple, highly repetitive sequences. Introns make up a large percentage of non-coding DNA. Some of this non-coding DNA is non-functional junk DNA, such as pseudogenes, but there is no firm consensus on the total amount of junk DNA.
A microsatellite is a tract of repetitive DNA in which certain DNA motifs are repeated, typically 5–50 times. Microsatellites occur at thousands of locations within an organism's genome. They have a higher mutation rate than other areas of DNA leading to high genetic diversity. Microsatellites are often referred to as short tandem repeats (STRs) by forensic geneticists and in genetic genealogy, or as simple sequence repeats (SSRs) by plant geneticists.
Genomics is an interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.
Michael Smith was a British-born Canadian biochemist and businessman. He shared the 1993 Nobel Prize in Chemistry with Kary Mullis for his work in developing site-directed mutagenesis. Following a PhD in 1956 from the University of Manchester, he undertook postdoctoral research with Har Gobind Khorana at the British Columbia Research Council in Vancouver, British Columbia, Canada. Subsequently, Smith worked at the Fisheries Research Board of Canada Laboratory in Vancouver before being appointed a professor of biochemistry in the UBC Faculty of Medicine in 1966. Smith's career included roles as the founding director of the UBC Biotechnology Laboratory and the founding scientific leader of the Protein Engineering Network of Centres of Excellence (PENCE). In 1996 he was named Peter Wall Distinguished Professor of Biotechnology. Subsequently, he became the founding director of the Genome Sequencing Centre at the BC Cancer Research Centre.
Molecular genetics is a branch of biology that addresses how differences in the structures or expression of DNA molecules manifests as variation among organisms. Molecular genetics often applies an "investigative approach" to determine the structure and/or function of genes in an organism's genome using genetic screens.
In genetics and bioinformatics, a single-nucleotide polymorphism is a germline substitution of a single nucleotide at a specific position in the genome that is present in a sufficiently large fraction of considered population.
Gene mapping or genome mapping describes the methods used to identify the location of a gene on a chromosome and the distances between genes. Gene mapping can also describe the distances between different sites within a gene.
The Human Genome Project (HGP) was an international scientific research projects with the goal of determining the base pairs that make up human DNA, and of identifying, mapping and sequencing all of the genes of the human genome from both a physical and a functional standpoint. It started in 1990 and was completed in 2003. It remains the world's largest collaborative biological project. Planning for the project started after it was adopted in 1984 by the US government, and it officially launched in 1990. It was declared complete on April 14, 2003, and included about 92% of the genome. Level "complete genome" was achieved in May 2021, with a remaining only 0.3% bases covered by potential issues. The final gapless assembly was finished in January 2022.
Whole genome sequencing (WGS), also known as full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.
Beijing Institute of Genomics (BIG) is a genomics research center of Chinese Academy of Sciences (CAS).
Cancer genome sequencing is the whole genome sequencing of a single, homogeneous or heterogeneous group of cancer cells. It is a biochemical laboratory method for the characterization and identification of the DNA or RNA sequences of cancer cell(s).
Optical mapping is a technique for constructing ordered, genome-wide, high-resolution restriction maps from single, stained molecules of DNA, called "optical maps". By mapping the location of restriction enzyme sites along the unknown DNA of an organism, the spectrum of resulting DNA fragments collectively serves as a unique "fingerprint" or "barcode" for that sequence. Originally developed by Dr. David C. Schwartz and his lab at NYU in the 1990s this method has since been integral to the assembly process of many large-scale sequencing projects for both microbial and eukaryotic genomes. Later technologies use DNA melting, DNA competitive binding or enzymatic labelling in order to create the optical mappings.
Stephen Wayne "Steve" Scherer is a Canadian scientist who currently serves as the Chief of Research at The Hospital for Sick Children (SickKids) and distinguished University Professor at the University of Toronto. He obtained his PhD at the University of Toronto under Professor Lap-chee Tsui. Together they founded Canada's first human genome centre, the Centre for Applied Genomics (TCAG). He is a Senior Fellow of Massey College at the University of Toronto. In 2014, he was named an esteemed Clarivate Citation laureate in Physiology or Medicine for the “Discovery of large-scale gene copy number variation and its association with specific diseases.”
Dr Vinod Scaria FRSB, FRSPH is an Indian biologist, medical researcher pioneering in Precision Medicine and Clinical Genomics in India. He is best known for sequencing the first Indian genome. He was also instrumental in the sequencing of The first Sri Lankan Genome, analysis of the first Malaysian Genome sequencing and analysis of the Wild-type strain of Zebrafish and the IndiGen programme on Genomics for Public Health in India.
Whole genome bisulfite sequencing is a next-generation sequencing technology used to determine the DNA methylation status of single cytosines by treating the DNA with sodium bisulfite before high-throughput DNA sequencing. The DNA methylation status at various genes can reveal information regarding gene regulation and transcriptional activities. This technique was developed in 2009 along with reduced representation bisulfite sequencing after bisulfite sequencing became the gold standard for DNA methylation analysis.
Elaine Ann Ostrander is an American geneticist at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) in Bethesda, Maryland. She holds a number of professional academic appointments, currently serving as Distinguished and Senior Investigator and head of the NHGRI Section of Comparative Genomics; and Chief of the Cancer Genetics and Comparative Genomics Branch. She is known for her research on prostate cancer susceptibility in humans and for conducting genetic investigations with the Canis familiaris —the domestic dog— model, which she has used to study disease susceptibility and frequency and other aspects of natural variation across mammals. In 2007, her laboratory showed that much of the variation in body size of domestic dogs is due to sequence changes in a single gene encoding a growth-promoting protein.
Personalized onco-genomics (POG) is the field of oncology and genomics that is focused on using whole genome analysis to make personalized clinical treatment decisions. The program was devised at British Columbia's BC Cancer Agency and is currently being led by Marco Marra and Janessa Laskin. Genome instability has been identified as one of the underlying hallmarks of cancer. The genetic diversity of cancer cells promotes multiple other cancer hallmark functions that help them survive in their microenvironment and eventually metastasise. The pronounced genomic heterogeneity of tumours has led researchers to develop an approach that assesses each individual's cancer to identify targeted therapies that can halt cancer growth. Identification of these "drivers" and corresponding medications used to possibly halt these pathways are important in cancer treatment.
Professor Susan J. Clark is an Australian biomedical researcher in epigenetics of development and cancer. She was elected a Fellow of the Australian Academy of Science in 2015, and is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and Research Director and Head of Genomics and Epigenetics Division at the Garvan Institute of Medical Research. Clark developed the first method for bisulphite sequencing for DNA methylation analysis and used it to establish that the methylation machinery of mammalian cells is capable of both maintenance and de novo methylation at CpNpG sites and showed is inheritable. Clark's research has advanced understanding of the role of DNA methylation, non-coding RNA and microRNA in embryogenesis, reprogramming, stem cell development and cancer and has led to the identification of epigenomic biomarkers in cancer. Clark is a founding member of the International Human Epigenome Consortium (IHEC) and President of the Australian Epigenetics Alliance (AEpiA).
Robert Holt, is a genomic scientist and immunogeneticist. He is currently a Distinguished Scientific at the BC Cancer Research Centre, where he is also Co-Director of the BC Cancer Immunotherapy program. He is also appointed as Professor of Medical Genetics at the University of British Columbia and Professor of Molecular Biology & Biochemistry at Simon Fraser University. Through international consortia, he has had made several significant contributions to science. After initial sequencing of the Drosophila and human genomes was co-PI on the NIH program to sequence the rat genome, and was also a PI on the international effort to sequence the malaria mosquito genome, which involved >30 principal scientists from 11 different countries. With his publications exceeding over 200 and his citations being recorded approximately 70,000 times, Holt earned a position in the top 1% of Web of Science cited researchers by Clarivate Analytics in 2018 and 2019.